Alerts
Friday 07 October 2022 from 13:00 to 14:10
Po.6 E- poster session 6: management and recommendations, old and new therapies/biologics
PO.6.131 A randomized, double-blind, placebo controlled study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-303, a potent dual baff/april inhibitor, in adult healthy volunteers